Procaps Group (NASDAQ:PROC) Trading Down 3%

Shares of Procaps Group S.A. (NASDAQ:PROC) were down 3% on Thursday . The company traded as low as $2.59 and last traded at $2.60. Approximately 9,167 shares traded hands during trading, a decline of 57% from the average daily volume of 21,215 shares. The stock had previously closed at $2.68.

Procaps Group Stock Performance

The business’s fifty day simple moving average is $3.03 and its two-hundred day simple moving average is $3.20. The company has a current ratio of 1.47, a quick ratio of 0.99 and a debt-to-equity ratio of 5.74.

Institutional Investors Weigh In On Procaps Group

Institutional investors and hedge funds have recently bought and sold shares of the stock. Exome Asset Management LLC acquired a new stake in shares of Procaps Group during the fourth quarter worth about $516,000. Millennium Management LLC raised its position in Procaps Group by 15.9% in the 2nd quarter. Millennium Management LLC now owns 101,430 shares of the company’s stock valued at $945,000 after purchasing an additional 13,908 shares during the last quarter. Citadel Advisors LLC acquired a new stake in Procaps Group during the 2nd quarter worth $263,000. Geode Capital Management LLC boosted its stake in Procaps Group by 13.7% during the 1st quarter. Geode Capital Management LLC now owns 21,223 shares of the company’s stock worth $96,000 after purchasing an additional 2,562 shares during the period. Finally, State Street Corp purchased a new position in Procaps Group during the 3rd quarter worth $89,000.

Procaps Group Company Profile

Procaps Group SA develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory.